Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GenVec - GNVC -- Ignore unavailable to you. Want to Upgrade?

To: Savant who wrote (78)	3/21/2016 9:24:30 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 106

I liked what was said at the quarterly webcast. It's quite clear that no safety problem exists in the hearing trial and it should be resumed at any time, or may actually have been resumed. I'm uncertain that Novartis must announce it, but the update in the clinical trials database indicating they're still recruiting is certainly a positive. It's my belief that GNVC cannot say something that either Novartis hasn't said, or released GNVC to say. GNVC may know the trial has resumed, but lacking NVS approval to say so, they may only hint on it occurring. What I found interesting was the emphasis on future partnerships. It sounds like they are in discussions with a variety of different companies on several possible drugs or vaccines. They made it sound like one or more of the partnerships should almost certainly be announced this year. Gary